• Breakthrough T1D awarded a grant to University of Florida researcher Michael J. Haller to support the PRISE-hATG study of SAB Biotherapeutics’ SAB-142.
• Trial targets Stage 3 type 1 diabetes patients 100 days to 2 years from diagnosis, testing beta-cell preservation via C-peptide measures.
• SAB BIO will co-fund the study, extending its SAB-142 program alongside the ongoing Phase 2b SAFEGUARD trial in new-onset Stage 3 T1D.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-296936), on July 07, 2026, and is solely responsible for the information contained therein.